Dexcom Q2 revenue $1.157B (+15% YoY); raises FY25 revenue guidance; CEO Sayer to retire, Jake Leach named CEO

DEXCOM INC

2025-Q2 EPS reported $0.71 revenue$2,193,100,000

Revenue $1.157B (+15% YoY); GAAP EPS $0.45, non-GAAP EPS $0.48.
Raises FY25 revenue guidance to $4.600-4.625B (14-15% growth); margins reiterated.
CEO Kevin Sayer to retire Jan 1, 2026; becomes Executive Chairman. COO Jake Leach promoted to CEO and Board.
FDA clearance for Dexcom G7 15 Day CGM System received in Q2.
U.S. revenue +15%, international +16% reported (+14% organic).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.